Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | The case for adjunctive therapies during thrombectomy for acute ischemic stroke

Elena Zapata Arriaza, MD, PhD, Seville Biomedical Research Institute, Seville, Spain, shares insights from a debate at WSC 2026 on the use of adjunctive therapies during thrombectomy for patients with acute ischemic stroke. Dr Zapata Arriaza makes the case for adjunctive therapies, highlighting that successful recanalization does not always translate into complete tissue reperfusion or optimal patient recovery.
This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Okay, I will talk in the presentation about the adjunctive therapies in the mechanical thrombectomy and I will try to focus on what mechanical thrombectomy leaves and results and in which scenarios these adjunctive therapies may help. We know that successful recanalization doesn’t mean tissue reperfusion. And this incomplete tissue reperfusion may lead to not full recovery, as we know in the trial...

Okay, I will talk in the presentation about the adjunctive therapies in the mechanical thrombectomy and I will try to focus on what mechanical thrombectomy leaves and results and in which scenarios these adjunctive therapies may help. We know that successful recanalization doesn’t mean tissue reperfusion. And this incomplete tissue reperfusion may lead to not full recovery, as we know in the trial. So we have to push this ceiling effect of the large vessel occlusion recanalization. And we should use an adjunctive therapy to improve the rates of complete recovery of the patient. So these adjunctive therapies may help because they try to improve the tissue reperfusion. And as far as we know in the trials, they have improved the excellent outcome. So we are trying to improve the complete recovery of the patients without any harm or mortality concerning the trials. So I will try to support these adjunctive therapies to keep pushing the limits and improve patient recovery.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.